JP2019514970A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514970A5
JP2019514970A5 JP2018558199A JP2018558199A JP2019514970A5 JP 2019514970 A5 JP2019514970 A5 JP 2019514970A5 JP 2018558199 A JP2018558199 A JP 2018558199A JP 2018558199 A JP2018558199 A JP 2018558199A JP 2019514970 A5 JP2019514970 A5 JP 2019514970A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antimetabolite
individual
bladder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018558199A
Other languages
English (en)
Japanese (ja)
Other versions
JP7712055B2 (ja
JP2019514970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031445 external-priority patent/WO2017193098A1/en
Publication of JP2019514970A publication Critical patent/JP2019514970A/ja
Publication of JP2019514970A5 publication Critical patent/JP2019514970A5/ja
Priority to JP2021172052A priority Critical patent/JP2022009327A/ja
Priority to JP2023206570A priority patent/JP2024028881A/ja
Application granted granted Critical
Publication of JP7712055B2 publication Critical patent/JP7712055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018558199A 2016-05-06 2017-05-05 下部尿路上皮がんを処置する方法 Active JP7712055B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021172052A JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法
JP2023206570A JP2024028881A (ja) 2016-05-06 2023-12-07 下部尿路上皮がんを処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US62/333,151 2016-05-06
US201762443614P 2017-01-06 2017-01-06
US62/443,614 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021172052A Division JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法

Publications (3)

Publication Number Publication Date
JP2019514970A JP2019514970A (ja) 2019-06-06
JP2019514970A5 true JP2019514970A5 (enExample) 2020-06-18
JP7712055B2 JP7712055B2 (ja) 2025-07-23

Family

ID=60203435

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018558199A Active JP7712055B2 (ja) 2016-05-06 2017-05-05 下部尿路上皮がんを処置する方法
JP2021172052A Withdrawn JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法
JP2023206570A Withdrawn JP2024028881A (ja) 2016-05-06 2023-12-07 下部尿路上皮がんを処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021172052A Withdrawn JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法
JP2023206570A Withdrawn JP2024028881A (ja) 2016-05-06 2023-12-07 下部尿路上皮がんを処置する方法

Country Status (23)

Country Link
US (1) US20190388338A1 (enExample)
EP (2) EP3452053B1 (enExample)
JP (3) JP7712055B2 (enExample)
KR (2) KR20220123317A (enExample)
CN (2) CN118453872A (enExample)
AU (1) AU2017261371B2 (enExample)
CA (1) CA3023274A1 (enExample)
ES (1) ES2940227T3 (enExample)
FI (1) FI3452053T3 (enExample)
HR (1) HRP20221544T1 (enExample)
HU (1) HUE060965T2 (enExample)
IL (2) IL295592A (enExample)
LT (1) LT3452053T (enExample)
MX (2) MX389296B (enExample)
NZ (3) NZ748252A (enExample)
PL (1) PL3452053T3 (enExample)
PT (1) PT3452053T (enExample)
RS (1) RS64032B1 (enExample)
RU (2) RU2022100624A (enExample)
SG (2) SG11201809838VA (enExample)
SI (1) SI3452053T1 (enExample)
SM (1) SMT202300047T1 (enExample)
WO (1) WO2017193098A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3370768T3 (da) 2015-11-03 2022-03-21 Janssen Biotech Inc Antistoffer som specifikt binder pd-1 og anvendelser deraf
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
SG10201913998YA (en) * 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
MX2020004771A (es) 2017-11-08 2020-10-19 Taris Biomedical Llc Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
EA023156B1 (ru) 2009-06-26 2016-04-29 ТАРИС Биомедикал ЛЛК Устройство для доставки лекарств
DK2512581T3 (da) 2009-12-17 2021-03-29 Taris Biomedical Llc Implanterbar indretning med intravesikal tolerance
MX343671B (es) * 2010-06-02 2016-11-16 Abraxis Bioscience Llc * Metodos de tratamiento de cancer de vejiga.
EP2600800B1 (en) 2010-08-05 2020-09-30 TARIS Biomedical LLC Ureteral stent drug delivery device and kit
BR112013019410A2 (pt) 2011-02-04 2019-09-24 Taris Biomedical Inc dispositivo implantável para liberação controlada de fármaco de solubilidade baixa
CN104470535A (zh) * 2012-03-29 2015-03-25 阿尔托生物科学有限公司 用于治疗肿瘤的方法
PL2890384T3 (pl) * 2012-08-31 2022-02-14 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza obejmujące oksaliplatynę
CA2882575C (en) 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
EP2964310A1 (en) 2013-03-05 2016-01-13 TARIS Biomedical LLC Drug delivery devices and methods for controlled drug release through device orifice
AU2014227914B2 (en) 2013-03-15 2018-05-10 Taris Biomedical Llc Drug delivery devices and methods for drug delivery
PT2968880T (pt) 2013-03-15 2025-07-07 Taris Biomedical Llc Dispositivos de aplicação de fármaco com componente permeável a fármaco
KR102503010B1 (ko) 2013-08-19 2023-02-24 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
CN119950539A (zh) 2014-03-06 2025-05-09 塔里斯生物医药公司 用吉西他滨来治疗膀胱癌的药物递送系统和方法
AU2015279674B2 (en) 2014-06-26 2020-07-23 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法

Similar Documents

Publication Publication Date Title
Lee et al. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy
JP2019514970A5 (enExample)
US10076528B2 (en) System and method for diagnosis and treatment
Antonia et al. Immuno-oncology combinations: a review of clinical experience and future prospects
JP2019522657A5 (enExample)
Goessl et al. The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction
RU2022100624A (ru) Способ лечения рака уротелия нижних путей
BR112020008537A2 (pt) inibidores duplos de vias da tim-3 e da pd-1
Shaikh et al. Engineering stent based delivery system for esophageal cancer using docetaxel
Denlinger et al. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers
Hoag et al. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review
Coloma et al. High incidence of cetuximab-related infusion reactions in head and neck patients
CN101612141B (zh) 丁丙诺啡贴剂
CN119923256A (zh) 包含大麻素的连续递送系统及其医药用途
Knight et al. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine
WO2025235493A1 (en) Casdatifan for use in the treatment of cancer
Islam et al. Marital Status and Survival in Patients with Multiple Myeloma: The Role of Marriage in the Management of Multiple Myeloma
JPWO2021062244A5 (enExample)
Seminario-Vidal et al. 283 Toxic epidermal necrolysis in the setting of acute graft-versus-host disease successfully treated with tumor necrosis factor alpha inhibitors
Vidal et al. Legionella in a patient with rheumatoid arthritis receiving abatacept
Yang et al. Hepatic Arterial Infusion Chemotherapy combined with Tislelizumab and Donafenib induced Toxic Epidermal Necrolysis in a Primary Liver Carcinoma Patient-A case report
HK40005970A (en) Method of treating lower tract urothelial cancer
BR122024005298A2 (pt) Usos de antimetabólitos no tratamento de câncer urotelial do trato inferior, kits e dispositivo de liberação
HK40044298A (en) Microbiome related immunotherapies